Aquestive Therapeutics, Inc.
AQST
$2.87
$0.020.70%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 57.56M | 58.90M | 58.36M | 51.50M | 50.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 57.56M | 58.90M | 58.36M | 51.50M | 50.58M |
| Cost of Revenue | 17.87M | 18.03M | 18.39M | 20.48M | 20.83M |
| Gross Profit | 39.69M | 40.87M | 39.97M | 31.02M | 29.75M |
| SG&A Expenses | 50.18M | 43.72M | 38.98M | 34.98M | 31.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 88.33M | 80.00M | 73.55M | 70.96M | 65.69M |
| Operating Income | -30.77M | -21.10M | -15.19M | -19.45M | -15.10M |
| Income Before Tax | -44.15M | -35.09M | -25.76M | -28.52M | -7.63M |
| Income Tax Expenses | -14.00K | 101.00K | -39.00K | 245.00K | 245.00K |
| Earnings from Continuing Operations | -44.14 | -35.19 | -25.72 | -28.77 | -7.87 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -44.14M | -35.19M | -25.72M | -28.77M | -7.87M |
| EBIT | -30.77M | -21.10M | -15.19M | -19.45M | -15.10M |
| EBITDA | -30.03M | -20.04M | -14.02M | -18.20M | -13.73M |
| EPS Basic | -0.52 | -0.45 | -0.36 | -0.43 | -0.11 |
| Normalized Basic EPS | -0.33 | -0.28 | -0.22 | -0.25 | -0.15 |
| EPS Diluted | -0.52 | -0.46 | -0.36 | -0.43 | -0.14 |
| Normalized Diluted EPS | -0.33 | -0.28 | -0.22 | -0.25 | -0.15 |
| Average Basic Shares Outstanding | 346.81M | 322.81M | 296.40M | 262.84M | 244.86M |
| Average Diluted Shares Outstanding | 346.81M | 322.81M | 296.40M | 262.84M | 263.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |